G6PD Deficiency Diagnosis and Management

Assay Selection and Interpretation

• A G6PD assay is generally sufficient for diagnosing G6PD deficiency in most patients, but the type of assay matters significantly—qualitative tests work well for males and homozygous females with severe deficiency, while quantitative assays or flow cytometry are necessary for heterozygous females and patients with concurrent hematological conditions 1
• Qualitative fluorescent spot tests are appropriate for detecting severe G6PD deficiency (enzyme activity <10% of normal) in males and homozygous females 1

Critical Timing Considerations

• Avoid testing during or immediately after acute hemolytic episodes, as reticulocytes and young RBCs may contain near-normal enzyme levels, potentially masking deficiency 2
• Wait at least 50 days after RBC transfusion before performing enzyme assays, as donor RBC contamination of 6-12% can cause false-negative results 2
• Testing 120 days post-transfusion is ideal but often impractical in frequently transfused patients 2
• Consider calculating the PK/G6PD ratio or comparing to controls with similar reticulocyte counts when interpreting borderline results 2

Clinical Context for Testing

• Qualitative screening is recommended before starting oxidant drugs (dapsone, primaquine, sulfonamides) in patients of Mediterranean, African, Indian, or Southeast Asian descent 1
• For P. vivax radical cure with tafenoquine, quantitative G6PD testing is required—do not use if activity is <70% 1
• Primaquine, rasburicase, and methylene blue are absolutely contraindicated in G6PD deficiency 1, 3

Special Considerations

• Molecular analysis may be required in females heterozygous for the disorder when enzymatic testing is inconclusive 1, 3
• Genetic testing helps identify specific variants (Mediterranean vs. African), which determines hemolytic risk severity and drug contraindications 1, 3
• The Mediterranean variant (Gdmed) causes life-threatening hemolysis requiring strict oxidant drug avoidance, while the African variant (GdA-) produces milder, self-limited hemolysis 1, 3
• Quantitative testing is needed to determine the degree of deficiency in borderline cases, particularly when considering weekly primaquine dosing 3
• Patients with 30-70% activity and non-Mediterranean variants can receive modified primaquine regimens with close monitoring 1
• Neutropenia may be present but is not a reliable screening marker for G6PD deficiency 1
• Testing whole blood without removing white cells and platelets prevents detection of deficiency in all cases examined 2
• Buffy coat removal or filtration is essential for accurate RBC enzyme measurement 2

G6PD Deficiency and Dapsone Therapy

Introduction to G6PD Deficiency

• The American College of Physicians recommends calculating the percentage of normal G6PD activity by dividing the patient's G6PD level by the laboratory upper limit of normal and multiplying by 100, to determine the risk of hemolysis with dapsone therapy 4

Alternative Therapies

• The American Academy of Dermatology suggests using alternative immunosuppressants such as mycophenolate, azathioprine, or methotrexate for dermatologic conditions in patients with G6PD deficiency 5
• The American Academy of Ophthalmology recommends using atovaquone or inhaled pentamidine for Pneumocystis prophylaxis in patients with G6PD deficiency 6

Management of Hemolysis

• The American Society of Hematology recommends immediately discontinuing dapsone and using ascorbic acid as an alternative treatment for methemoglobinemia in G6PD-deficient patients 7
• The American Society of Hematology suggests considering exchange transfusion for severe cases of hemolysis and monitoring for rebound methemoglobinemia requiring repeat dosing every 6-8 hours for up to 2-3 days after dapsone exposure 7
• The American Society of Hematology recommends screening first-degree relatives of G6PD-deficient patients and screening before initiating any oxidant drugs in patients of Mediterranean, African, Indian, or Southeast Asian descent 8

Screening Recommendations

• The Infectious Diseases Society of America recommends screening before initiating any oxidant drugs in patients of Mediterranean, African, Indian, or Southeast Asian descent 4

Quantitative G6PD Analysis in Clinical Practice

Primary Indications for Quantitative Testing

• Infants with rapidly rising total serum bilirubin (TSB) approaching exchange transfusion levels or not responding to phototherapy require quantitative G6PD testing as part of the evaluation, according to the American Academy of Pediatrics 9
• Quantitative G6PD testing is recommended for infants receiving phototherapy with TSB rising rapidly and crossing percentiles unexpectedly, as stated by the American Academy of Pediatrics 9
• For infants with jaundice in the first 24 hours or excessive jaundice for age, measuring G6PD as part of the laboratory evaluation is suggested by the American Academy of Pediatrics 9

Specific Clinical Algorithms

For Neonatal Hyperbilirubinemia

• Quantitative G6PD should be measured when TSB is approaching exchange levels, as recommended by the American Academy of Pediatrics 9
• G6PD testing should be considered when jaundice appears in the first 24 hours of life, according to the American Academy of Pediatrics 9
• G6PD deficiency was identified as the cause in 31.5% of infants who developed kernicterus in one series, highlighting the importance of quantitative G6PD testing in this population, as reported by the American Academy of Pediatrics 9

Ascorbic Acid Dosing in G6PD Deficiency

Therapeutic Use and Risks

• Ascorbic acid is the treatment of choice for methemoglobinemia in G6PD-deficient patients when methylene blue is contraindicated, according to the American Journal of Hematology 10
• The doses recommended for treating methemoglobinemia (0.5-10 g) exceed the FDA-mandated RDA limit for G6PD-deficient patients, creating a clinical dilemma where the benefit of treating life-threatening methemoglobinemia outweighs hemolysis risk 10
• Exchange transfusion should be considered for severe cases of ascorbic acid-induced hemolysis in G6PD-deficient patients 10

Guidelines for Accurate G6PD Quantitative Testing and Clinical Interpretation

Testing Timing and Patient‑Related Factors

• Avoid G6PD testing during or immediately after an acute hemolytic episode because the surge of reticulocytes and young red cells, which contain near‑normal enzyme levels, can produce falsely elevated activity results that mask true deficiency. 11
• Do not perform G6PD testing within 50–120 days of an allogeneic red‑cell transfusion; donor red cells (constituting roughly 6–12 % of the sample) can artificially raise measured activity and lead to false‑negative findings. 11
• Record the current reticulocyte count at the time of sampling; a high reticulocyte proportion can normalize the overall G6PD activity despite underlying deficiency, and interpretation should incorporate a PK/G6PD ratio or comparison with controls of similar reticulocyte levels. 11

Laboratory Methodology and Sample Preparation

• Use a quantitative G6PD assay that normalizes activity to hemoglobin rather than a qualitative fluorescent spot test, to obtain an accurate enzymatic measurement. 11
• Ensure proper red‑cell purification before analysis (e.g., removal of the buffy coat or filtration) to eliminate white‑cell and platelet interference that can obscure deficiency detection. 11
• Document the specific assay platform, reference range, and upper limit of normal for the laboratory; variability in methodology and reference standards can affect the interpretation of a numeric result. 11

Interpretation of Quantitative Results

• Calculate the percentage of normal activity by dividing the patient’s G6PD value by the laboratory’s upper limit of normal and multiplying by 100; this percentage guides medication safety decisions. 11
• Recognize that values <30 % of normal indicate severe deficiency, for which oxidant drugs such as primaquine, tafenoquine, dapsone, rasburicase, and methylene blue are absolutely contraindicated. 11
• Values between 30 % and 70 % represent intermediate deficiency, requiring variant‑specific management (e.g., modified primaquine dosing for African‑type variants). 11

Clinical Implications Beyond Hemolysis

• G6PD deficiency influences multiple organ systems: it increases risk of hemolysis, contributes to neonatal hyperbilirubinemia, renders hemoglobin A1c an unreliable marker for diabetes monitoring, and complicates anemia assessment. 12

Common Pitfalls to Avoid

• Never rely on historical G6PD results when the timing of the test, transfusion history, or reticulocyte count are unknown; repeat quantitative testing under optimal conditions is required. 11
• Never use qualitative spot tests alone for medication‑related decision‑making; quantitative assays are essential for accurate risk stratification. 11
• Never perform testing during an acute hemolytic crisis, as the resulting false‑elevated activity can lead to inappropriate clinical decisions. 11

Guidelines for G6PD Testing Prior to Methylene‑Blue Use in Methemoglobinemia

Testing Recommendations

• All symptomatic patients with methemoglobinemia should undergo G6PD‑deficiency testing before receiving methylene blue, and ideally every patient considered for methylene blue should be tested. [13][14]

Emergency Management

• When immediate methylene‑blue therapy is unavoidable, a rapid family‑history inquiry for G6PD deficiency should be obtained before drug administration. 14
• If G6PD deficiency is suspected or confirmed and methylene blue cannot be safely used, alternative therapies such as high‑dose ascorbic acid (approximately 0.5–10 g) or exchange transfusion should be considered. 13

Risks of Methylene‑Blue in G6PD‑Deficient Patients

• Methylene blue may precipitate severe hemolytic anemia and paradoxically worsen methemoglobinemia in individuals with G6PD deficiency. [15][14]
• The underlying mechanism is that G6PD is the first enzyme of the hexose‑monophosphate shunt, providing the sole source of NADPH in erythrocytes. 14
• G6PD‑deficient patients cannot generate sufficient NADPH to reduce methylene blue to leukomethylene blue, rendering the antidote ineffective. 14
• High doses of methylene blue (> 4 mg/kg) act as an oxidant rather than a reducing agent, leading to Heinz‑body hemolytic anemia. [15][14]